Brought to you by 
Proteostasis raises $45mm through Series A round
21 Apr 2021
Executive Summary
Proteostasis Therapeutics (treatments for genetic and degenerative diseases) brought in $45mm through its Series A round. Seed investor HealthCare Ventures returned, and was joined by new participants Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund, and Genzyme Ventures.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Proteostasis raises $45mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice